CDK4/6 Inhibitors in Advanced HR+/HER2 - Breast Cancer: A Multicenter Real-World Data Analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36876172/
Our RWD analysis on CDK4/6i treatment in Germany supports data from RCTs regarding both treatment efficacy and safety of CDK4/6i for treatment of patients with HR+/HER2- ABC. In comparison to...
Conclusion: Our RWD analysis on CDK4/6i treatment in Germany supports data from RCTs regarding both treatment efficacy and safety of CDK4/6i for treatment of patients with HR+/HER2- ABC. In comparison to data from the pivotal RCTs, median PFS was lower but within the expected range for RWD, which could result from inclusion of patients with...
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA - PharmacoEconomics
Source : https://link.springer.com/article/10.1007/s40273-023-01245-y
Background and Objective Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors improve progression-free survival when combined with endocrine therapies in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast...
Conclusions: At a willingness to pay of $100,000/QALY gained, our model predicts that combining CDK4/6 inhibitors plus letrozole is not cost effective with a marginal increase in QALYs at a high cost. Lowering the cost of these drugs or identifying patients who can receive maximal benefit from CDK4/6 inhibitors would improve the value of this...
Update Breast Cancer 2022 Part 5 - Early Stage Breast Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36908285/
The treatment of patients with early stage breast cancer has changed in recent years due to the introduction of pembrolizumab, olaparib, and abemaciclib. These and other drugs with the same...
Conclusions/Relevance: This review article summarizes the latest results that have either been presented at major conferences such as the ESMO 2022 or published recently in international journals. This includes reports on newly discovered breast cancer genes, atezolizumab in neoadjuvant therapy in HER2-positive patients, long-term data from...
Multi-Targeted and On-Demand Non-Coding RNA Regulation Nanoplatform against Metastasis and Recurrence of Triple-Negative Breast Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36905244/
Dysregulation of microRNAs (miRs) is the hallmark of triple-negative breast cancer (TNBC), which is closely involved with its growth, metastasis, and recurrence. Dysregulated miRs are promising targets for TNBC therapy,...
Conclusions/Relevance: This MTOR system opens a new avenue for on-demand regulation of disordered miRs against growth, metastasis, and recurrence of TNBC.
A Study on the Effectiveness of Deep Learning-Based Anomaly Detection Methods for Breast Ultrasonography - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36905074/
In the medical field, it is delicate to anticipate good performance in using deep learning due to the lack of large-scale training data and class imbalance. In particular, ultrasound, which...
Conclusions/Relevance: Our experimental results showed that the sliced-Wasserstein autoencoder model outperformed the anomaly detection performance of others. However, anomaly detection using the reconstruction-based approach may not be effective because of the occurrence of numerous false-positive values. In the following studies, reducing...